We aim to transform therapy selection and drug discovery and development by building the world’s largest library of human ex vivo tumor-derived organoids* that are characterized by molecular features and associated clinical outcomes in robust, reproducible 3D models.Contact Us
Client-selected organoids screened with or without allogeneic MHC-matched PBMCs, tailored to your research needs. A variety of compound classes can be screened ranging from small molecules to biologics, viral vectors, cell engagers, and cellular therapies.
Predefined models for routine screening in organoids containing actionable alterations across cancer types. Compounds can be screened alone and in combinations, providing a rapid and cost-effective alternative to in vivo preclinical animal experiments.
Characterize cell populations of interest with precision–identify and validate complex signatures and identify biomarkers of therapeutic response
Uncover spatio-temporal patterns of gene expression in two dimensions to better characterize the relationships between molecular profiles and therapeutic response
commercially available biological models
of tumor organoids with Tempus xT solid tumor comprehensive profiling
3D confocal imaging assays with AI analytics on every tumor organoid drug sensitivity screen
of automation-driven assays enable expedited experimental processes
Individual human ex vivo tumor-derived organoids* are screened in Tempus’ high-throughput environment. Tempus organoids are NGS-qualified and have been pre-screened against a panel of chemotherapies and small molecule therapeutics. Our 3D models serve as the basis for drug screening efforts for drug discovery and development.
Organoids are grown in proprietary chemically defined conditions from core biopsies or surgical resections.
Organoid histology is verified by board-certified medical pathologists.
Full transcriptomic profiles are generated by RNA sequencing.
Tumor mutation recapitulation is assessed by overlap of somatic variants between tumor and tumor organoids via the Tempus xT 648 gene panel.
Organoids are phenotyped via high content assays, which are then analyzed via automated machine vision algorithms employing state-of-the-art computer vision models to segment organoids, quantify infiltrating immune cells, and predict drug efficacies along with other clinical endpoints as desired.
*Specimens collected under IRB-approved research protocols
Larsen et al. optimize a pan-cancer platform with tumor organoids from over 1,000 patients and establish standards for culture conditions, molecular characterization, and therapeutic profiling using deep learning coupled with light microscopy.READ PUBLICATION
Khare et al. demonstrate the scalability and throughput of a machine vision tumor organoid immune co-culture platform across multiple unique patient-derived tumor organoid lines bearing a target of interest, enabling future discovery of biomarkers of therapeutic response and resistance.READ PUBLICATION
Hanker et al. show that patient-derived organoids established from ER+ MBC biopsies represent valuable models to understand and explore diverse mechanisms of CDK4/6i resistance.READ PUBLICATION
We’ve created a biological modeling infrastructure centered on ex vivo tumor organoids to help you accelerate your research needs.
Thank you for contacting Tempus. We will respond shortly.